Zacks Research Issues Optimistic Estimate for MMSI Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Stock analysts at Zacks Research raised their Q1 2025 EPS estimates for Merit Medical Systems in a research report issued on Thursday, October 24th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $0.81 for the quarter, up from their previous estimate of $0.80. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.31 per share. Zacks Research also issued estimates for Merit Medical Systems' Q2 2025 earnings at $0.98 EPS, FY2025 earnings at $3.68 EPS, Q2 2026 earnings at $1.11 EPS and FY2026 earnings at $4.03 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.04. Merit Medical Systems had a return on equity of 15.29% and a net margin of 9.02%. The business had revenue of $338.00 million during the quarter, compared to the consensus estimate of $334.94 million.

MMSI has been the topic of a number of other research reports. Wells Fargo & Company increased their target price on Merit Medical Systems from $85.00 to $103.00 and gave the stock an "equal weight" rating in a research note on Monday, September 16th. Bank of America lifted their target price on Merit Medical Systems from $92.00 to $103.00 and gave the stock a "neutral" rating in a report on Monday, September 16th. Barrington Research reaffirmed an "outperform" rating and set a $114.00 price target on shares of Merit Medical Systems in a research report on Friday, October 18th. StockNews.com raised shares of Merit Medical Systems from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $110.00 target price (up from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Merit Medical Systems currently has an average rating of "Moderate Buy" and an average price target of $101.82.

Merit Medical Systems Stock Performance

MMSI traded down $0.69 on Monday, reaching $95.31. The company had a trading volume of 343,915 shares, compared to its average volume of 436,123. The stock has a market cap of $5.54 billion, a P/E ratio of 55.34, a P/E/G ratio of 2.41 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.64 and a current ratio of 6.24. Merit Medical Systems has a fifty-two week low of $65.46 and a fifty-two week high of $101.60. The company's fifty day moving average is $96.11 and its 200 day moving average is $87.26.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. boosted its stake in shares of Merit Medical Systems by 2.9% during the second quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier's stock valued at $362,000 after purchasing an additional 118 shares in the last quarter. Xponance Inc. boosted its position in Merit Medical Systems by 4.9% during the 2nd quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier's stock worth $311,000 after buying an additional 170 shares during the period. Entropy Technologies LP grew its holdings in Merit Medical Systems by 6.5% during the 1st quarter. Entropy Technologies LP now owns 3,314 shares of the medical instruments supplier's stock worth $251,000 after acquiring an additional 203 shares during the last quarter. Park Avenue Securities LLC increased its position in Merit Medical Systems by 5.9% in the 3rd quarter. Park Avenue Securities LLC now owns 3,991 shares of the medical instruments supplier's stock valued at $394,000 after acquiring an additional 223 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Merit Medical Systems by 19.7% during the second quarter. Blue Trust Inc. now owns 1,426 shares of the medical instruments supplier's stock valued at $123,000 after acquiring an additional 235 shares during the last quarter. Institutional investors own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.